Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Novartis Venture Funds leads Visiogen's $40mm Series E round

Executive Summary

Novartis Venture Funds has led the $40mm Series E financing for Visiogen (presbyopia- and cataract-correcting devices) and contributed a new board member. Technology Partners, another first-time investor, also contributed significantly and was joined by existing backers Three Arch Partners, New Leaf Venture Partners, Prospect Venture Partners, CMEA Ventures, and Foundation Medical Partners. The company will use the money to fund global commercialization of its accommodating intra-ocular lens Synchrony, which was recently launched in Europe and could be approved in the US next year. Including this round, Visiogen has raised over $80mm since it was founded in 2001.
Deal Industry
  • Medical Devices
    • Implantable Devices
Deal Status
  • Final
Deal Type
  • Financing
    • Private Placement

Related Companies

Advertisement
UsernamePublicRestriction

Register